마더리스크라운드

1. Drugs R D. 2016 Sep;16(3):251-254.
Safety of Mebendazole Use During Lactation: A Case Series
Report.
Karra N1,2
, Cohen R3,4
, Berlin M4
, Dinavitser N4
, Koren G3,5
, Berkovitch M3,4,6
.
Author information
 1
The Motherisk Program, Zerifin, Israel. nour_karra@yahoo.com.
 2
Clinical Pharmacology Unit, Assaf Harofeh Medical Center, 70300, Zerifin, Israel.
 3
The Motherisk Program, Zerifin, Israel.
 4
Clinical Pharmacology Unit, Assaf Harofeh Medical Center, 70300, Zerifin, Israel.
 5
The Motherisk Program, Hospital for Sick Children and University of Toronto, Toronto, Canada.
Abstract
INTRODUCTION:
Mebendazole is an effective drug widely used in the treatment of parasitic infections.
Although theoretically considered as safe during lactation, no studies have evaluated its
potential adverse effects in infants of breastfeeding mothers.
OBJECTIVES:
We aimed to evaluate the safety of mebendazole in infants of lactating women treated
with the drug.
METHODS:
Women referred for consultation regarding mebendazole use were invited to participate in
the study. Overall 45 lactating women treated with various protocols of mebendazole were
recruited in this case series study.
RESULTS:
Regardless of the treatment protocol used (single or repeated doses) mebendazole was
well tolerated and was not associated with any adverse effects in infants of lactating
mothers. There was mild GI irritability in two treated women.
CONCLUSION:

2. This study provides first evidence in humans as to the safety of mebendazole in
breastfeeding
Clin Endocrinol (Oxf). 2016 Aug 26.
Antithyroid drugs during breastfeeding.
Hudzik B1, Zubelewicz-Szkodzinska B2,3.
Author information
 1
Third Department of Cardiology, Silesian Centre for Heart Disease, SMDZ in Zabrze, Medical
University of Silesia in Katowice, Zabrze, Poland. bartekh@mp.pl.
 2
Department of Nutrition-Related Disease Prevention, School of Public Health in Bytom, Medical
University of Silesia in Katowice, Bytom, Poland.
 3
Department of Endocrinology, County Hospital, Piekary Slaskie, Poland.
Abstract
Antithyroid drugs (ATDs) are widely used for the treatment of Graves' disease (GD) in the
general population. Over the past decade, there has been an increasing awareness that
several disturbances of thyroid function may occur in mothers after delivery which may be
more prevalent than previously appreciated. Exacerbation of immune reactions occurs 3-12
month following delivery. Management of hyperthyroidism during lactation requires
special considerations and should be implemented to prevent any adverse outcomes in
mother and neonate. Continuation of breastfeeding is safe and should be encouraged in
hyperthyroid mothers taking ATDs, whether these are ATDs being continued after gestation
or indeed ATD treatment initiated in the postpartum period. Given PTU hepatotoxicity
concerns, experts currently recommend using low-to-moderate MMI doses as a first-line
therapy in lactating mothers. PTU should be reserved only as a second-line agent for cases
of severe hyperthyroidism (thyroid storm) and allergic reactions to previous MMI treatment.
ATD should be administered in divided doses immediately following each feeding. Evaluation
of thyroid function tests is advisable at least 3-4 weeks after the initiation of breastfeeding.
© 2016 John Wiley & Sons Ltd.

3. J Pharm Biomed Anal. 2016 Sep 10;129:502-8. doi: 10.1016/j.jpba.2016.07.047. Epub 2016
Jul 30.
Development and validation of a bioanalytical method for
five antidepressants in human milk by LC-MS.
Salazar FR1, D'Avila FB2, de Oliveira MH2, Ferreira PL2, Bergold AM2.
Author information
 1
Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Av.
Ipiranga 2752, 90610-000 Porto Alegre, RS, Brazil. Electronic address: nandi.salazar@gmail.com.
 2
Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Av.
Ipiranga 2752, 90610-000 Porto Alegre, RS, Brazil.
Abstract
The use of medications during lactation is a common practice; however, pharmacological
treatments impose serious doubts to both professionals and nursing mothers regarding the
safety of drugs used during this period. Most of drugs are excreted in breast milk and there is
great variability in the amount of analytes that can be received by the infant. Dilemmas about
breastfeeding arise most commonly in relation to postpartum depression. Depression is a
major clinical problem during the postpartum period and the vulnerability to onset or
recurrence of depressive symptoms increases the possibility of psychotropic drug use
during lactation. Selective inhibitors of serotonin reuptake are commonly prescribed for the
treatment of depressive disorders, including fluoxetine, sertraline, citalopram, and
paroxetine. A validated bioanalytical method using liquid chromatography coupled to mass
spectrometry was developed and validated for determination of antidepressants in human
milk following protein precipation. The bioanalytical method was successfully applied to
assess milk samples from nursing mothers. From found concentrations, infant absolute
(4.36-12.26μg/kg/day) and relative dose (0.60-2.90%) were estimated and low values were
obtained indicating safe use during lactation. However, other factors such as complemantary
feeding and hepatic or renal disorders in the infant should be considered.
Copyright © 2016 Elsevier B.V. All rights reserved.